Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Bleomycin/cisplatin/etoposide

Bleomycin/cisplatin/etoposide Reactions 1680, p71 - 2 Dec 2017 Neutropenia, anaemia and thrombocytopenia: 2 case reports A 16-year-old girl and a 19-year-old woman were described, who developed neutropenia and anaemia or neutropenia, anaemia and thrombocytopenia each, during treatment with bleomycin, cisplatin and etoposide [not all outcomes stated; durations of treatments to reactions onsets not stated]. Patient 1: A 16-year-old girl was diagnosed with stage IIIc small cell ovarian cancer, and was initiated on chemotherapy with the BEP regimen, which consisted of bleomycin, cisplatin and etoposide [routes and dosages not stated]. She received three cycles of chemotherapy and subsequently developed grade 4 afebrile neutropenia and grade 1 anaemia. Her disease progressed, and her regimen was changed to irinotecan and doxorubicin-liposomal. She showed disease progression, and died 6 months after the initial diagnosis of small cell ovarian cancer. Patient 2: A 19-year-old woman was diagnosed with small cell ovarian cancer, and was initiated on chemotherapy with the BEP regimen, which consisted of bleomycin, cisplatin and etoposide. She received two cycles of chemotherapy and subsequently developed grade 4 neutropenia, grade 2 anaemia and grade 4 thrombocytopenia. She was treated with unspecified granulocyte colony stimulating factors [GCSF] and erythropoietin. Her anaemia responded well to erythropoietin http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Bleomycin/cisplatin/etoposide

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Download PDF
1 page

Bleomycin/cisplatin/etoposide

Abstract

Reactions 1680, p71 - 2 Dec 2017 Neutropenia, anaemia and thrombocytopenia: 2 case reports A 16-year-old girl and a 19-year-old woman were described, who developed neutropenia and anaemia or neutropenia, anaemia and thrombocytopenia each, during treatment with bleomycin, cisplatin and etoposide [not all outcomes stated; durations of treatments to reactions onsets not stated]. Patient 1: A 16-year-old girl was diagnosed with stage IIIc small cell ovarian cancer, and was initiated on...
Loading next page...
 
/lp/springer-journals/bleomycin-cisplatin-etoposide-woym9KrN3G

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
DOI
10.1007/s40278-017-39002-y
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p71 - 2 Dec 2017 Neutropenia, anaemia and thrombocytopenia: 2 case reports A 16-year-old girl and a 19-year-old woman were described, who developed neutropenia and anaemia or neutropenia, anaemia and thrombocytopenia each, during treatment with bleomycin, cisplatin and etoposide [not all outcomes stated; durations of treatments to reactions onsets not stated]. Patient 1: A 16-year-old girl was diagnosed with stage IIIc small cell ovarian cancer, and was initiated on chemotherapy with the BEP regimen, which consisted of bleomycin, cisplatin and etoposide [routes and dosages not stated]. She received three cycles of chemotherapy and subsequently developed grade 4 afebrile neutropenia and grade 1 anaemia. Her disease progressed, and her regimen was changed to irinotecan and doxorubicin-liposomal. She showed disease progression, and died 6 months after the initial diagnosis of small cell ovarian cancer. Patient 2: A 19-year-old woman was diagnosed with small cell ovarian cancer, and was initiated on chemotherapy with the BEP regimen, which consisted of bleomycin, cisplatin and etoposide. She received two cycles of chemotherapy and subsequently developed grade 4 neutropenia, grade 2 anaemia and grade 4 thrombocytopenia. She was treated with unspecified granulocyte colony stimulating factors [GCSF] and erythropoietin. Her anaemia responded well to erythropoietin

Journal

Reactions Weekly – Springer Journals

Published: Dec 2, 2017

There are no references for this article.